Boston Scientific Floats Taxus Base Price; J&J Counters TAXUS IV In Court
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific is invoking clinical data from the TAXUS IV trial's diabetic patient subset to thwart Johnson & Johnson's attempt to enjoin U.S. sales of the Express2 and Taxus stents
You may also be interested in...
Boston Scientific Taxus Inventory Of 150,000 Planned For U.S. Launch
Boston Scientific projects a 60% U.S. drug-eluting stent market penetration "right out of the gate" for its soon-to-be-launched Taxus, according to Senior VP and Cardiovascular Group President Paul LaViolette
Boston Scientific Taxus Inventory Of 150,000 Planned For U.S. Launch
Boston Scientific projects a 60% U.S. drug-eluting stent market penetration "right out of the gate" for its soon-to-be-launched Taxus, according to Senior VP and Cardiovascular Group President Paul LaViolette
Taxus Clears Legal Hurdle As Judge Denies J&J/Cordis Injunction Request
The arguments made by Boston Scientific and Johnson & Johnson/Cordis in the ongoing drug-eluting stent patent dispute both have merit, according to Wilmington, Del. federal court Judge Sue Robinson